Our Story


Frontier Biotech was co-founded by three distinguished industry veterans, Dr. Dong Xie, Dr. Changjin Wang, and Dr. Rongjian Lu.  Hailed as one of the leading biotechnology companies in China in the field of innovative drug development for HIV and AIDS treatments, Frontier Biotech has been the recipient of numerous awards and accolades over the years.  The company was named as one of the “Cultivation of Unicorn Enterprises” in the city of Nanjing, China.

                    Frontier Biotechnologies Inc.(Nanjing)


Frontier Biotech is an innovation-driven biopharmaceutical company. Through more than a decade of committed effort, Frontier Biotech has built an extraordinary team with international vision and deep expertise in new drug development and established a fully integrated state-of-the-art long-acting peptide new drug innovation plat form with global intellectual properties. In addition to the launch of Aikening ®, a Category 1 product and the first long-acting HIV fusion inhibitor in the world, Frontier Biotech is advancing an array of clinical assets through our R&D pipeline.  This includes multiple programs reaching Phase 1 and 2 clinical trials in China and the United States.

Frontier Biotech established its headquarter, R&D center and manufacturing facility in Nanjing, China. The existing solid-phase peptide synthesis and freeze-dry injectable product lines are GMP-certified by the National Medical Products Administration (NMPA) as part of the Aikening ®'s approval process.  In addition to building a strong core team for R&D, development, manufacturing and commercial operation, Frontier Biotech has been successfully leveraging strategic partnerships, collaboration and licensing relationships to shorten the development cycle and mitigate the development risk.  This allows Frontier Biotech to collaborate with manufacturers and commercial distributors to bring innovative medicines to patients as quickly and safely as possible.


Develop Innovative Therapies to Better Human Lives